Table 1. Demographic Characteristics of the Participants at Baseline.*.
| Characteristic | BNT162b2 (N=22,026) |
Placebo (N=22,021) |
Total (N=44,047) |
|---|---|---|---|
| Sex — no. (%) | |||
| Male | 11,322 (51.4) | 11,098 (50.4) | 22,420 (50.9) |
| Female | 10,704 (48.6) | 10,923 (49.6) | 21,627 (49.1) |
| Race or ethnic group — no. (%)† | |||
| White | 18,056 (82.0) | 18,064 (82.0) | 36,120 (82.0) |
| Black or African American | 2,098 (9.5) | 2,118 (9.6) | 4,216 (9.6) |
| Asian | 952 (4.3) | 942 (4.3) | 1,894 (4.3) |
| American Indian or Alaska Native | 221 (1.0) | 217 (1.0) | 438 (1.0) |
| Native Hawaiian or other Pacific Islander | 58 (0.3) | 32 (0.1) | 90 (0.2) |
| Multiracial | 550 (2.5) | 533 (2.4) | 1,083 (2.5) |
| Not reported | 91 (0.4) | 115 (0.5) | 206 (0.5) |
| Ethnicity† | |||
| Hispanic or Latinx | 5,704 (25.9) | 5,695 (25.9) | 11,399 (25.9) |
| Not reported | 111 (0.5) | 114 (0.5) | 225 (0.5) |
| Country — no. (%) | |||
| Argentina | 2,883 (13.1) | 2,881 (13.1) | 5,764 (13.1) |
| Brazil | 1,452 (6.6) | 1,448 (6.6) | 2,900 (6.6) |
| Germany | 249 (1.1) | 250 (1.1) | 499 (1.1) |
| South Africa | 401 (1.8) | 399 (1.8) | 800 (1.8) |
| Turkey | 249 (1.1) | 249 (1.1) | 498 (1.1) |
| United States | 16,792 (76.2) | 16,794 (76.3) | 33,586 (76.3) |
| Age group at vaccination — no. (%) | |||
| 16–55 yr | 13,069 (59.3) | 13,095 (59.5) | 26,164 (59.4) |
| >55 yr | 8,957 (40.7) | 8,926 (40.5) | 17,883 (40.6) |
| Age at vaccination — yr | |||
| Median | 51.0 | 51.0 | 51.0 |
| Range | 16–89 | 16–91 | 16–91 |
| SARS-CoV-2 status — no. (%)‡ | |||
| Positive | 689 (3.1) | 716 (3.3) | 1,405 (3.2) |
| Negative | 21,185 (96.2) | 21,180 (96.2) | 42,365 (96.2) |
| Missing data | 152 (0.7) | 125 (0.6) | 277 (0.6) |
| Body-mass index — no. (%)§ | |||
| ≥30.0: obese | 7,543 (34.2) | 7,629 (34.6) | 15,172 (34.4) |
| Missing data | 7 (<1) | 6 (<1) | 13 (<1) |
Data are summarized for participants 16 years of age or older in the safety population. The demographic characteristics of participants 12 to 15 years of age were reported previously.11 Percentages may not total 100 because of rounding. SARS-CoV-2 denotes severe acute respiratory syndrome coronavirus 2.
Race and ethnicity were reported by the participants. The categories shown are those that were used to collect the data.
Positive status was defined as a positive N-binding antibody result or a positive nucleic acid amplification test (NAAT) result at visit 1 or medical history of coronavirus disease 2019 (Covid-19). Negative status was defined as a negative N-binding antibody result or a negative NAAT result at visit 1 and no medical history of Covid-19.
The body-mass index is the weight in kilograms divided by the square of the height in meters.